Annalise Enterprise CXR Triage Trauma
Annalise-AI Pty Ltd • Radiology • 03/28/2023
Device Purpose
Annalise Enterprise CXR Triage Trauma is a software tool utilizing a deep-learning artificial intelligence algorithm to analyze adult chest X-rays for features suggestive of vertebral compression fractures, aiming to prioritize these cases in clinical worklists. The system integrates with PACS/RIS and demonstrated high diagnostic accuracy (AUC 0.954) and specific sensitivity/specificity performance in identifying vertebral compression fractures from erect CXRs, thereby facilitating expedited review for clinicians in specialized bone health programs.
Summary
Annalise Enterprise CXR Triage Trauma is an AI-powered software workflow tool designed to assist clinicians in the medical care environment. Its primary function is to analyze adult chest X-ray (CXR) studies to identify features suggestive of vertebral compression fractures. The system employs a convolutional neural network, trained using deep-learning techniques on diverse datasets, to detect these findings. Upon identification, the device integrates with existing Picture Archiving and Communication Systems (PACS) or Radiology Information Systems (RIS) to provide case-level output, enabling worklist prioritization or triage, specifically for clinicians in Bone Health and Fracture Liaison Service programs. It operates in parallel with standard clinical workflows and is not intended for standalone diagnostic decision-making, to direct attention to specific image portions other than vertebral compression fractures, or to rule out other critical findings. The device's performance was validated through a standalone, retrospective study using 589 CXR cases (272 positive for vertebral compression fracture, 317 negative) independent of the training data, sourced from four US hospital networks, with ground truth established by board-certified radiologists. For vertebral compression fractures, the AI algorithm demonstrated an Area Under the Curve (AUC) of 0.954 (95% CI: 0.939-0.968). At specific operating points, it achieved sensitivities of 89.3% (95% CI: 85.7-93.0) and 85.3% (95% CI: 80.9-89.3) with corresponding specificities of 89.0% (95% CI: 85.8-92.1) and 90.9% (95% CI: 87.7-94.0) respectively. The system also showed an average triage turn-around time of 30.0 seconds, though a noted limitation is that the performance evaluation was conducted using only erect positioning CXRs, and performance with supine positioning may differ.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the device's performance change when analyzing CXRs taken with supine positioning, given the current evaluation was limited to erect positioning?; What specific impact does the 30-second average triage turn-around time have on overall patient management and outcomes in Bone Health and Fracture Liaison Service programs?; Beyond vertebral compression fractures, are there plans to expand the AI algorithm's capability to detect other subtle or commonly missed traumatic findings on chest X-rays?; How does the algorithm differentiate between acute and chronic vertebral compression fractures, or does it flag all such fractures regardless of suspected acuity?; What were the characteristics of the false positive and false negative cases in the standalone performance study for vertebral compression fractures, and what strategies could further refine the algorithm's accuracy?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly